MX2022015834A - Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda. - Google Patents

Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda.

Info

Publication number
MX2022015834A
MX2022015834A MX2022015834A MX2022015834A MX2022015834A MX 2022015834 A MX2022015834 A MX 2022015834A MX 2022015834 A MX2022015834 A MX 2022015834A MX 2022015834 A MX2022015834 A MX 2022015834A MX 2022015834 A MX2022015834 A MX 2022015834A
Authority
MX
Mexico
Prior art keywords
sulcardine
administration
treatment
atrial fibrillation
acute atrial
Prior art date
Application number
MX2022015834A
Other languages
English (en)
Inventor
Robert Goodenow
Mireille Gillings
Gary Elliott
Jay Mason
Waldemar Radziszewski
Suzanne Romano
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of MX2022015834A publication Critical patent/MX2022015834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan composiciones y métodos para la administración de sulcardina a un sujeto que la necesita.
MX2022015834A 2020-06-12 2021-06-11 Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda. MX2022015834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
MX2022015834A true MX2022015834A (es) 2023-04-04

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015834A MX2022015834A (es) 2020-06-12 2021-06-11 Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda.

Country Status (13)

Country Link
US (2) US11813245B2 (es)
EP (1) EP4164633A1 (es)
JP (1) JP2023529196A (es)
KR (1) KR20230024347A (es)
CN (1) CN116723836A (es)
AU (1) AU2021288056A1 (es)
BR (1) BR112022025216A2 (es)
CA (1) CA3182015A1 (es)
CL (1) CL2022003501A1 (es)
CO (1) CO2023000194A2 (es)
IL (1) IL298907A (es)
MX (1) MX2022015834A (es)
WO (1) WO2021252959A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CN102665714A (zh) * 2009-11-17 2012-09-12 沪亚生物国际有限责任公司 心房纤颤的治疗
ES2569123T3 (es) * 2009-11-17 2016-05-06 Huya Bioscience International Llc Infusión lenta de sulcardina y sus sales
EP3302442A4 (en) 2015-06-03 2019-02-06 Triastek, Inc. PHARMACEUTICAL FORM AND USE THEREOF
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
WO2018137686A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
KR20210135990A (ko) * 2018-12-13 2021-11-16 후야 바이오사이언스 인터내셔널 엘엘씨 급성 심방 세동의 치료를 위한 설카르딘 투여
BR112021014640A8 (pt) * 2019-01-29 2022-12-20 Huya Bioscience Int Llc Sais de sulcardina

Also Published As

Publication number Publication date
JP2023529196A (ja) 2023-07-07
CA3182015A1 (en) 2021-12-16
KR20230024347A (ko) 2023-02-20
US11813245B2 (en) 2023-11-14
US20210386708A1 (en) 2021-12-16
US20240058304A1 (en) 2024-02-22
IL298907A (en) 2023-02-01
WO2021252959A1 (en) 2021-12-16
BR112022025216A2 (pt) 2023-04-04
CL2022003501A1 (es) 2023-06-09
EP4164633A1 (en) 2023-04-19
CN116723836A (zh) 2023-09-08
AU2021288056A1 (en) 2023-02-09
CO2023000194A2 (es) 2023-03-27

Similar Documents

Publication Publication Date Title
ZA202104166B (en) Sulcardine administration for treatment of acute atrial fibrillation
PH12018502634A1 (en) Topical compositions of apremilast
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2022004051A (es) Composicion novedosa para el cuidado de la piel.
MX2021009652A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX370624B (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
WO2018143552A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
WO2023081830A3 (en) Compositions and treatments with nirogacestat
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2022004054A (es) Composicion novedosa para el cuidado de la piel.
MX2022004052A (es) Composicion novedosa para el cuidado de la piel.
PE20200600A1 (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc
MX363200B (es) Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022004055A (es) Composicion novedosa para el cuidado de la piel.
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
MX2022015834A (es) Administracion de sulcardina para el tratamiento de fibrilacion auricular aguda.
MX2022015488A (es) Tratamiento para la disfuncion auricular.
MX2022002245A (es) Compuesto y metodos para tratar enfermedades relacionadas con oxalato.